Clinical trial
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
NCT01774344 · Bayer, Industry · Completed
Key facts
| NCT number | NCT01774344 |
|---|---|
| Title | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma |
| Official title | A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib |
| Acronym | RESORCE |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | Regorafenib (Stivarga, BAY73-4506), Placebo |
| Enrollment | 573 |
| Start date | May 14, 2013 |
| Primary completion | Feb 29, 2016 |
| Completion | Jul 5, 2019 |
| First posted | Jan 24, 2013 |
| Last update posted | Aug 20, 2020 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, China, Czechia, France, Germany, Hungary, Italy, Japan and 9 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: